Edition:
United States

Genfit SA (GNFT.PA)

GNFT.PA on Paris Stock Exchange

20.72EUR
14 Dec 2018
Change (% chg)

€-0.28 (-1.33%)
Prev Close
€21.00
Open
€20.78
Day's High
€20.92
Day's Low
€20.34
Volume
86,337
Avg. Vol
157,255
52-wk High
€28.28
52-wk Low
€17.67

Latest Key Developments (Source: Significant Developments)

Genfit Announces Positive Phase 2 Results From Study Of Elafibranor In Primary Biliary Cholangitis
Thursday, 6 Dec 2018 01:41am EST 

Dec 6 (Reuters) - GENFIT SA ::REG-GENFIT: POSITIVE PHASE 2 RESULTS FROM STUDY OF ELAFIBRANOR IN PRIMARY BILIARY CHOLANGITIS.SUBSTANTIAL REDUCTIONS IN ALKALINE PHOSPHATASE IN PATIENTS RECEIVING ELAFIBRANOR; 52% (80 MG) AND 44% (120 MG) WHEN COMPARED TO PLACEBO.ELAFIBRANOR SUCCESSFULLY MEETS PRIMARY ENDPOINT WITH HIGH STATISTICAL SIGNIFICANCE OF P<0.001.SIGNIFICANT RESPONSE RATE ON COMPOSITE ENDPOINT USED FOR REGULATORY APPROVAL, WITH 67% (80 MG) AND 79% (120 MG) RESPONDERS VERSUS 6.7% FOR PLACEBO (P15%, AND TOTAL BILIRUBIN (TB) Full Article

Genfit Launches U.S. Phase 2 Investigator-Initiated Study With Nitazoxanide In Patients With NASH-Induced Fibrosis
Monday, 3 Dec 2018 02:02am EST 

Dec 3 (Reuters) - GENFIT SA ::REG-GENFIT: LAUNCH OF A U.S. PHASE 2 INVESTIGATOR-INITIATED STUDY WITH NITAZOXANIDE IN PATIENTS WITH NASH-INDUCED FIBROSIS.ANTI-FIBROTIC EFFECT OF NITAZOXANIDE TO BE EVALUATED BY SEVERAL APPROACHES INCLUDING AN INNOVATIVE METHOD TO QUANTIFY HEPATIC FIBROGENESIS FLUX RATES.GENFIT HAS BEEN GRANTED A U.S. PATENT FOR USE OF NITAZOXANIDE IN NASH-INDUCED LIVER FIBROSIS.  Full Article

Genfit's Q1 revenues edge up compared to a year ago
Friday, 27 Apr 2018 02:04am EDT 

April 27 (Reuters) - Genfit SA ::* Revenues for the first three months of 2018 amounted to €37 thousand compared to €26 thousand for the same period in 2017.* At March 31, 2018, the Company's cash and cash equivalents amounted to €255.2 million compared with €137.0 million one year earlier.* At December 31, 2017, cash and cash equivalents totaled €273.8 million.  Full Article

Genfit FY Net Loss Widens To 58.6 Million Euros
Tuesday, 13 Mar 2018 12:53pm EDT 

March 13 (Reuters) - GENFIT SA ::2017: A YEAR OF VERY SIGNIFICANT REINFORCEMENT OF THE CASH POSITION (€274M AT 12.31.2017), WITH ALL PROGRAMS IN THE COMPANY'S PIPELINE MOVING FORWARD.RESULTS OF PHASE 2 STUDY OF ELAFIBRANOR IN PBC AND FILING OF AN IND APPLICATION FOR LAUNCH OF A PHASE 2 STUDY IN FIBROSIS EXPECTED IN 2018.FY NET LOSS EUR 58.6 MILLION VERSUS LOSS OF EUR 33.7 MILLION YEAR AGO.FY OPERATING LOSS EUR ‍​56.7 MILLION VERSUS LOSS OF EUR 34.2 MILLION YEAR AGO.FY REVENUES AND OTHER INCOME EUR 6.9 MILLION VERSUS EUR 6.8 MILLION YEAR AGO.  Full Article

Genfit announces positive outcome of DSMB safety review
Wednesday, 22 Nov 2017 12:18pm EST 

Nov 22 (Reuters) - GENFIT SA ::REG-GENFIT: POSITIVE OUTCOME FROM THE 18-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR.‍SAFETY DATA REVIEWED BY DSMB WHICH RECOMMENDED CONTINUATION OF TRIAL WITHOUT ANY MODIFICATIONS​.‍POSITIVE OUTCOME OF REVIEW ALLOWS GENFIT TO ACTIVELY PURSUE ITS EFFORT IN ENROLLING PATIENTS AND CONTINUATION OF RESOLVE-IT TRIAL​.‍POSITIVE OUTCOME CONFIRMS GOOD SAFETY PROFILE OF ELAFIBRANOR​.  Full Article

Genfit completes offering of convertible bonds due 2022 for 180 million euros
Tuesday, 17 Oct 2017 02:30am EDT 

Oct 17 (Reuters) - GENFIT SA ::REG-GENFIT COMPLETES A €180 MILLION OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022.‍OFFERING WAS MULTIPLE TIMES OVERSCRIBED, INITIAL AMOUNT OF OFFERING WAS INCREASED FROM EUR 150 MILLION TO EUR 180 MILLION​.NOMINAL UNIT VALUE OF THE OCEANES WAS SET AT €29.60, REPRESENTING A CONVERSION/EXCHANGE PREMIUM OF 30% TO CO’S REFERENCE SHARE PRICE‍​.‍OCEANES BEAR INTEREST AT AN ANNUAL NOMINAL RATE OF 3.50% PAYABLE SEMI-ANNUALLY IN ARREARS ON APRIL 16, AND OCT 16 OF EACH YEAR​.  Full Article

Genfit completes convertible bonds offering for amount of 180 million euros
Wednesday, 11 Oct 2017 08:20am EDT 

Oct 11 (Reuters) - GENFIT SA ::REG-GENFIT ANNOUNCES THE SUCCESS OF ITS OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF €180 MILLION.‍INITIAL AMOUNT OF EUR 150 MILLION HAS BEEN INCREASED TO EUR 180 MILLION IN ACCORDANCE WITH CORPORATE AUTHORIZATIONS OF COMPANY​.  Full Article

Genfit launches an offering of conbertible bonds for around 150 million euros
Wednesday, 11 Oct 2017 01:33am EDT 

Oct 11 (Reuters) - GENFIT SA ::GENFIT LAUNCHES AN OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF APPROXIMATELY €150 MILLION.‍OCEANES WILL BEAR INTEREST AT AN ANNUAL NOMINAL RATE COMPRISED BETWEEN 3.00% AND 3.50% PAYABLE SEMI-ANNUALLY​.‍NOMINAL UNIT VALUE OF OCEANES WILL BE SET AT A CONVERSION/EXCHANGE PREMIUM OF BETWEEN 30% AND 35% TO GENFIT'S REFERENCE SHARE PRICE​.BONDS TO BE REDEEMED AT PAR ON OCT 16, 2022.‍​.  Full Article

Genfit reports‍ nine months revenues at 91 thousand euros
Wednesday, 11 Oct 2017 01:31am EDT 

Oct 11 (Reuters) - GENFIT SA : :‍CASH AND CASH EQUIVALENTS OF EUR 113.8 MILLION AT SEPTEMBER 30, 2017​.‍REVENUES FOR FIRST NINE MONTHS OF 2017 OF EUR 91 THOUSAND​.  Full Article

Genfit H1 operating loss widens to 22.4 million euros
Monday, 25 Sep 2017 12:09pm EDT 

Sept 25 (Reuters) - GENFIT SA ::REG-GENFIT: 2017 HALF-YEAR RESULTS: CASH POSITION AT END OF PERIOD AT €126M AND SIGNIFICANT ADVANCES IN THE COMPANY'S PIPELINE.H1 NET LOSS EUR ‍​22.6 MILLION VERSUS LOSS OF EUR 12.7 MILLION YEAR AGO.H1 OPERATING LOSS EUR 22.4 MILLION VERSUS LOSS OF EUR 12.8 MILLION YEAR AGO.H1 REVENUE EUR 4.7 MILLION VERSUS EUR 3.6 MILLION YEAR AGO.BY END OF YEAR, EXPECTS TO HAVE FILED APPLICATION FOR AUTHORIZATION TO LAUNCH PHASE 2 TRIAL TO EVALUATE EFFICACY OF NITAZOXANIDE IN LIVER FIBROSIS​.EXPECTS RESEARCH AND DEVELOPMENT COSTS TO CONTINUE TO INCREASE IN H2 2017.EXPECTS TO SIGN NEW COLLABORATIONS FOR FURTHER VALIDATION OF GENFIT DIAGNOSTIC TEST.PLANS TO SUBMIT TO FDA APPLICATION FOR AUTHORIZATION TO LAUNCH FIRST PROOF-OF-CONCEPT PHASE 2 STUDY OF NITAZOXANIDE IN NASH PATIENTS WITH ADVANCED FIBROSIS, BEFORE END OF YEAR.  Full Article